CytomX Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
CTMX$1.98-9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(569) | $(99,317) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Amortization of intangible assets | 146 | 146 |
| Depreciation and amortization | 2,029 | 2,297 |
| Impairment loss on machinery and equipment | — | 254 |
| Accretion of discounts on short-term investments | (7,419) | (52) |
| Stock-based compensation expense | 8,558 | 13,125 |
| Non-cash lease expense | 3,729 | 3,413 |
| Changes in operating assets and liabilities | ||
| Accounts receivable | 32,554 | (35,196) |
| Prepaid expenses and other current assets | 2,471 | (3,181) |
| Other assets | (56) | 874 |
| Accounts payable | (1,426) | 68 |
| Accrued liabilities and other long-term liabilities | (7,041) | (9,784) |
| Deferred revenue | (89,011) | 16,565 |
| Net cash used in operating activities | $(56,035) | $(110,788) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (840) | (1,740) |
| Purchases of short term investments | (424,834) | — |
| Maturities of short term investments | 275,000 | 100,000 |
| Net cash (used in) provided by investing activities | $(150,674) | $98,260 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of pre-funded warrants and warrants, net of issuance cost | 29,669 | — |
| Proceeds from employee stock purchase plan and exercise of stock options | 561 | 648 |
| Net cash provided by financing activities | $30,230 | $648 |
| Net decrease in cash, cash equivalents and restricted cash | (176,479) | (11,880) |
| Cash, cash equivalents and restricted cash, beginning of year | 194,567 | 206,447 |
| Cash, cash equivalents and restricted cash, end of year | $18,088 | $194,567 |
| Supplemental disclosures of noncash investing items: | ||
| Purchases of property and equipment in accounts payable and accrued liabilities | $75 | $6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.